Freedom Capital Markets maintains Buy rating on Omada Health, $35 price target
Freedom Capital Markets reiterated a Buy rating and $35 price target for Omada Health, implying a 91.3% upside. The firm cites strong demand for Omada's integrated care solutions and resilience against competitors.
How this was made

The 30-second read
Why it matters
The rating update provides a modest bullish cue but lacks new material events; traders may watch for subsequent earnings or partnership news.
Market read
Analyst rating change offers limited trading impetus; relevance is low to moderate for investors in health‑tech equities.
What to watch
Potential competitive pressure from larger tech‑health players not reflected in the rating.
Background
Freedom Capital Markets reiterated a Buy rating on Omada Health with a $35 price target, citing demand for integrated care and competitive positioning.
Market effects
Analyst rating may modestly influence health‑tech sector sentiment.
Limited to U.S. investors tracking digital health stocks.
Minimal global impact.
Counterpoint
Rating maintenance may be seen as a neutral signal; price target could be overly optimistic.
Key entities
- AnalystFreedom Capital Markets
Research firm issuing the rating.
- CompanyOmada Health
Digital health firm targeted by the rating.

